Tema-Ghana, Nov. 1, CDA Consult – The Institut Pasteur de Dakar (IPD) has announced the launch of a new programme to advance the development of measles, and rubella vaccines for manufacture in Darka, Senegal.
Dr. Amadou Alpha Sall, IPD Chief Executive Officer said: “By manufacturing affordable measles and rubella vaccines and diagnostics in Africa, the region will be one step closer to a diversified manufacturing landscape for epidemic preparedness and improving the supply chain for essential vaccines for routine immunization.
“This will help countries in the region build autonomy and reach every child with lifesaving vaccines”.
Dr Sall in a paper copied to the Communication for Development and Advocacy Consult (CDA Consult) in Tema said IPD will produce the vaccine for essential, routine immunization campaigns in low- and middle-income countries and for any outbreak and catch-up campaigns.
She explained that the technology transfer of the MR vaccine is supported by the Bill & Melinda Gates Foundation in collaboration with Batavia Biosciences and the Univercells Group.
Dr. Sall said the vaccines would be manufactured with grants by the Bill & Melinda Gates Foundation which will deploy Batavia’s Hip-Vax intensified production process for GMP measles and rubella material and Univercells’ NevoLine™ technology platform to accelerate manufacturing and affordable access to essential and epidemic vaccines in Africa.
She said the production would be transferred to the state-of-the-art MADIBA facility, a regional manufacturing hub for COVID-19 and other epidemic vaccines with a capacity to produce 300 million doses for use in Africa.
Dr. Christopher Yallop, Chief Operating Officer of Batavia Biosciences added: “We are privileged to be able to work with Institut Pasteur de Dakar and the Bill & Melinda Gates Foundation to advance this innovative vaccine technology with a key manufacturing partner.
“Our HIP-Vax manufacturing process technology, developed on the NevoLine™ platform, is designed to deliver vaccines at high yield and very low cost, increasing affordability and availability.”
José Castillo, co-founder of Univercells, commented: “We are honoured to partner with Institut Pasteur de Dakar and Batavia Biosciences, and to participate in this historic initiative that will increase access to the measles and rubella vaccines on the African continent and across the globe.
“Supporting and nurturing biomanufacturing autonomy is at the heart of Univercells’ mission, and we are thrilled that our technology will help enable progress towards regional autonomy.
“Knowing that our breakthrough vaccine manufacturing platform NevoLine™, initially funded by the Bill & Melinda Gates Foundation in 2016, will now help accelerate the manufacture of vaccines in Africa, is very exciting.”.
The Institut Pasteur de Dakar (IPD) is a Senegalese private foundation in the public interest with the mission to advance public health and wellbeing in Africa by conducting research, providing training and education, sharing scientific knowledge, and advancing biotechnology.
Since its founding in 1896, IPD has been at the forefront of the fight against infectious diseases in West Africa. IPD is one of the four WHO prequalified manufacturers to supply yellow fever vaccine to UN’s Agencies.
Univercells is a global life sciences company with the mission of making biologics accessible to all. Using our combined expertise in scaling, production, and bioprocessing, Univercells finds new and sustainable ways to widen access to life-changing drugs.
Batavia Biosciences significantly contributes to ease human suffering from infectious diseases and cancer by leveraging our innovative technologies and in-depth know-how at all stages of the development trajectory, from the transition into early clinical studies, to navigating late stage clinical development and entering commercial manufacturing at higher speed, reduced costs, and with increased success.
The company operates state-of-the-art development and manufacturing facilities in Europe and the US and, as part of the CJ CheilJedang global family, is building a strong position in global health with its strategic partners worldwide
